Transforming the gene therapy landscape
with AI-powered AAV vectors
with AI-powered AAV vectors
The Outlook
Gene therapies of the future will be designed using artificial intelligence (AI) to reach more patients and treat many more diseases.OUR SCIENCE
Read about our scientists' publications in Science, Nature Biotechnology, at ASGCT and more.SERIES A FINANCING
Dyno closes $100 million Series A financing led by Andreessen HorowitzPARTNERING & LICENSING
Astellas for AAV vectors directed to skeletal and cardical muscle
Roche for AAV vectors directed to CNS and liver
Sarepta for next-gen gene therapy vectors for muscle disease
Novartis for ocular collaboration to develop improved gene therapies
ANNOUNCEMENTS
Dyno Therapeutics to Present New Data on Optimized AAV Capsids with Transformative Therapeutic Delivery Potential at 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Dyno Therapeutics Launches the Dyno bCap 1™ Capsid Product, a Breakthrough CNS Gene Delivery Vector Created with Generative Artificial Intelligence
AWARDS
2023 & 2022 FORBES LIST: AMERICA’S BEST STARTUP EMPLOYEER For the second year in a row, Dyno is recognized on the Forbes list of America’s Best Startup Employers
NEVY AWARDS Dyno named Emerging Company of the Year by the New England Venture Capital Association
ENDPOINTS NEWS Dyno named one of the most promising startups of 2021
